Literature DB >> 8521680

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

L Bertilsson1.   

Abstract

The isoenzymes which catalyse the polymorphic hydroxylations of debrisoquine/sparteine and S-mephenytoin are cytochromes P450 2D6 and P450 2C19 (CYP2D6 and CYP2C19), respectively. CYP2D6 is involved in the stereospecific metabolism of several important groups of drugs, for example antiarrhythmics, antidepressants and neuroleptics. About 7% of Caucasians but only 1% of Orientals are poor metabolisers (PMs) of debrisoquine. The most common mutated allele CYP2D6B in Caucasian PMs is almost absent from their Oriental counterparts. On the other hand, the mean activity of CYP2D6 in Oriental extensive metabolisers (EMs) is lower than that in Caucasian EMs. This is due to the frequent distribution of a partially deficient CYP2D6 allele causing a Pro34-->Ser amino acid exchange in as many as 50% of Oriental alleles. This is the molecular genetic basis for slower metabolism of antidepressants and neuroleptics observed in Oriental compared with Caucasian people, and consequently for the lower dosages of these drugs used. While CYP2D6 catalyses the metabolism of lipophilic bases only, CYP2C19 is involved in the metabolism of acids (e.g. S-mephenytoin), bases (e.g. imipramine and omeprazole) and neutral drugs (e.g. diazepam). About 3% of Caucasians and 12 to 22% of Orientals are PMs of S-mephenytoin. Polymerase chain reaction-based genotyping techniques recently became available for the two CYP2C19 mutated alleles m1 and m2, which cause no enzyme to be expressed. M1 accounts for about 80% of the mutations responsible for the PM phenotypes in Caucasians, Oriental and Black people. Diazepam is partially demethylated by CYP2C19, and the high frequency of mutated alleles in Orientals is probably the reason why such populations have a slower metabolism and are treated with lower doses of diazepam than Caucasians. Omeprazole is to a major extent hydroxylated by CYP2C19, and there is an approximately 10-fold difference in oral clearance between EMs and PMs of S-mephenytoin. The separation of Caucasians from Orientals is fairly recent in the evolutionary process (40,000 to 60,000 years ago); the separation of Black from Caucasian/Oriental people occurred much earlier, about 150,000 years ago. As pronounced differences have been found between Caucasians and Orientals in the CYP2D6 and CYP2C19 enzymes, it might be expected that Black people will show even greater differences in this respect. Some studies have been performed with Black participants, but the picture is not clear. The mean CYP2D6 activity in Black EMs seems to be lower than that in Caucasian EMs and similar to that of Oriental EMs.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521680     DOI: 10.2165/00003088-199529030-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  87 in total

1.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

2.  Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

Authors:  M Eichelbaum; M P Baur; H J Dengler; B O Osikowska-Evers; G Tieves; C Zekorn; C Rittner
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

3.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

4.  Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.

Authors:  Q Y Yue; J O Svensson; C Alm; F Sjöqvist; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

5.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.

Authors:  E Steiner; L Iselius; G Alván; J Lindsten; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

Authors:  K Brøsen; E Skjelbo; B B Rasmussen; H E Poulsen; S Loft
Journal:  Biochem Pharmacol       Date:  1993-03-24       Impact factor: 5.858

8.  Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.

Authors:  W E Evans; M V Relling; A Rahman; H L McLeod; E P Scott; J S Lin
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.

Authors:  E Skjelbo; K Brøsen; J Hallas; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1991-01       Impact factor: 6.875

10.  Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.

Authors:  A Llerena; G Edman; J Cobaleda; J Benítez; D Schalling; L Bertilsson
Journal:  Acta Psychiatr Scand       Date:  1993-01       Impact factor: 6.392

View more
  98 in total

1.  Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.

Authors:  S Hägg; O Spigset; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 2.  The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone.

Authors:  G Lurcott
Journal:  Anesth Prog       Date:  1998

Review 3.  Azole interactions with multidrug therapy in pediatric oncology.

Authors:  Antonio Ruggiero; Roberta Arena; Andrea Battista; Daniela Rizzo; Giorgio Attinà; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

Review 4.  Analgesics and breast-feeding: safety considerations.

Authors:  O Spigset; S Hägg
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

5.  Observational study of the impact of short-term duloxetine treatment on body weight in patients with major depressive disorder: a taiwanese perspective.

Authors:  Chien-Han Lai
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 6.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

7.  Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes.

Authors:  Li-Qun Yang; Wei-Feng Yu; Yun-Fei Cao; Bin Gong; Qing Chang; Guang-Shun Yang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 8.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Authors:  Krista L Lanctôt; Nathan Herrmann; Kenneth K Yau; Lyla R Khan; Barbara A Liu; Maysoon M LouLou; Thomas R Einarson
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

Review 9.  Classics in chemical neuroscience: diazepam (valium).

Authors:  Nicholas E Calcaterra; James C Barrow
Journal:  ACS Chem Neurosci       Date:  2014-02-27       Impact factor: 4.418

10.  Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.

Authors:  Li-Qun Yang; Shen-Jing Li; Yun-Fei Cao; Xiao-Bo Man; Wei-Feng Yu; Hong-Yang Wang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.